• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Humanigen, Inc. (Amendment)

    6/28/21 8:37:11 PM ET
    $HGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HGEN alert in real time by email
    SC 13D/A 1 humanigen13da6-062821.htm
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C.  20549
    SCHEDULE 13D
    (RULE 13D - 101)
    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a)
    (Amendment No. 6)*
    Humanigen, Inc.
    (Name of Issuer)
    Common Stock, par value $0.001
    (Title of Class of Securities)
    444863 10 4
    (CUSIP Number)
    Eric S. Wagner, Esq.
    Kleinberg, Kaplan, Wolff & Cohen, P.C.
    500 Fifth Avenue, New York, New York 10110
    (212) 986-6000
    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    June 18, 2021
    (Date of Event which Requires Filing of this Statement)
    If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box [ ].
    Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See Rule 13d-7 for other parties to whom copies are to be sent.
    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    1.
    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
     
    Black Horse Capital LP
       
    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
     
    (a)    [ ]
     
    (b)    [ ]
       
    3.
    SEC USE ONLY
       
    4.
    SOURCE OF FUNDS
       
     
    WC
       
    5.
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)      [ ]
       
    6.
    CITIZENSHIP OR PLACE OF ORGANIZATION
       
     
    Delaware
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
       
    7.
    SOLE VOTING POWER
       
     
    972,361
       
    8.
    SHARED VOTING POWER
       
     
    0
       
    9.
    SOLE DISPOSITIVE POWER
       
     
    972,361
       
    10.
    SHARED DISPOSITIVE POWER
       
     
    0
       
    11.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
     
    972,361
       
    12.
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11)
    EXCLUDES CERTAIN SHARES    [ ]
       
    13.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
       
     
    1.6%
       
    14.
    TYPE OF REPORTING PERSON
       
     
    PN




    1.
    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
     
    Black Horse Capital Master Fund Ltd.
       
    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
     
    (a)    [ ]
     
    (b)    [ ]
       
    3.
    SEC USE ONLY
       
    4.
    SOURCE OF FUNDS
       
     
    WC
       
    5.
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)      [ ]
       
    6.
    CITIZENSHIP OR PLACE OF ORGANIZATION
       
     
    Cayman Islands
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
       
    7.
    SOLE VOTING POWER
       
     
    0
       
    8.
    SHARED VOTING POWER
       
     
    2,243,807
       
    9.
    SOLE DISPOSITIVE POWER
       
     
    0
       
    10.
    SHARED DISPOSITIVE POWER
       
     
    2,243,807
       
    11.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
     
    2,243,807
       
    12.
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11)
    EXCLUDES CERTAIN SHARES    [ ]
       
    13.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
       
     
    3.8%
       
    14.
    TYPE OF REPORTING PERSON
       
     
    CO




    1.
    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
     
    Cheval Holdings, Ltd.
       
    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
     
    (a)    [ ]
     
    (b)    [ ]
       
    3.
    SEC USE ONLY
       
    4.
    SOURCE OF FUNDS
       
     
    WC
       
    5.
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)      [ ]
       
    6.
    CITIZENSHIP OR PLACE OF ORGANIZATION
       
     
    Cayman Islands
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
       
    7.
    SOLE VOTING POWER
       
     
    0
       
    8.
    SHARED VOTING POWER
       
     
    8,220,079
       
    9.
    SOLE DISPOSITIVE POWER
       
     
    0
       
    10.
    SHARED DISPOSITIVE POWER
       
     
    8,220,079
       
    11.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
     
    8,220,079
       
    12.
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11)
    EXCLUDES CERTAIN SHARES    [ ]
       
    13.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
       
     
    13.9%
       
    14.
    TYPE OF REPORTING PERSON
       
     
    CO




    1.
    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
     
    Black Horse Capital Management LLC
       
    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
     
    (a)    [ ]
     
    (b)    [ ]
       
    3.
    SEC USE ONLY
       
    4.
    SOURCE OF FUNDS
       
     
    OO
       
    5.
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)      [ ]
       
    6.
    CITIZENSHIP OR PLACE OF ORGANIZATION
       
     
    Delaware
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
       
    7.
    SOLE VOTING POWER
       
     
    9,192,440
       
    8.
    SHARED VOTING POWER
       
     
    0
       
    9.
    SOLE DISPOSITIVE POWER
       
     
    9,192,440
       
    10.
    SHARED DISPOSITIVE POWER
       
     
    0
       
    11.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
     
    9,192,440
       
    12.
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11)
    EXCLUDES CERTAIN SHARES    [ ]
       
    13.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
       
     
    15.6%
       
    14.
    TYPE OF REPORTING PERSON
       
     
    OO




    1.
    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
     
    Dale Chappell
       
    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
     
    (a)    [ ]
     
    (b)    [ ]
       
    3.
    SEC USE ONLY
       
    4.
    SOURCE OF FUNDS
       
     
    OO
       
    5.
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)      [ ]
       
    6.
    CITIZENSHIP OR PLACE OF ORGANIZATION
       
     
    Malta
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
       
    7.
    SOLE VOTING POWER
       
     
    33,440
       
    8.
    SHARED VOTING POWER
       
     
    11,436,247
       
    9.
    SOLE DISPOSITIVE POWER
       
     
    33,440
       
    10.
    SHARED DISPOSITIVE POWER
       
     
    11,436,247
       
    11.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
     
    11,469,687
       
    12.
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11)
    EXCLUDES CERTAIN SHARES    [ ]
       
    13.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
       
     
    19.4%
       
    14.
    TYPE OF REPORTING PERSON
       
     
    IN


    The following constitutes Amendment No. 6 (“Amendment No. 6”) to the Schedule 13D dated July 11, 2013 filed by the Reporting Persons with respect to the shares of common stock, par value $0.001 (the “Shares”), of Humanigen, Inc. (the “Issuer”), as previously amended (the “Schedule 13D”). This Amendment No. 6 amends the Schedule 13D as specifically set forth herein.
    Item 3.
    Source and Amount of Funds or Other Consideration.
    A total of approximately $18,560,150 was paid to acquire the Shares reported as beneficially owned by the Reporting Persons.  The funds used to purchase these securities were obtained from the general working capital of the Domestic Fund, the Offshore Fund and Cheval and margin account borrowings made in the ordinary course of business, although the Reporting Persons cannot determine whether any funds allocated to purchase such securities were obtained from any margin account borrowings.
    Item 5.
    Interest in Securities of the Issuer.
    Sub-clause (a) of Item 5 is hereby amended and restated in its entirety as follows:
    “(a)            The aggregate percentage of Shares reported owned by each person named herein is based upon 59,083,706 Shares outstanding as of May 5, 2021, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on May 13, 2021.
    As of the date hereof, the Domestic Fund may be deemed to beneficially own 972,361 Shares, the Offshore Fund may be deemed to beneficially own 2,243,807 Shares and Cheval may be deemed to beneficially own 8,220,079 Shares, constituting approximately 1.6%, 3.8% and 13.9%, respectively, of the outstanding Shares.
    BH Management, by virtue of its relationships with Domestic Fund and Cheval discussed in further detail in Item 2, may be deemed to beneficially own the 9,192,440 Shares beneficially owned by the Domestic Fund and Cheval, constituting approximately 15.6% of the outstanding Shares.
    Mr. Chappell, by virtue of his relationships with the Domestic Fund, the Offshore Fund and Cheval discussed in further detail in Item 2 of the Schedule 13D, may be deemed to beneficially own the 11,436,247 Shares collectively owned by the Domestic Fund, the Offshore Fund and Cheval.  Mr. Chappell also personally owns options that are exercisable within the next 60 days for 33,440 Shares.  Together, this constitutes approximately 19.4% of the outstanding Shares.”
    Sub-clause (c) is hereby amended and restated in its entirety as follows:
    “(c)            As described in further detail in Item 4 of Amendment No. 4 to the Schedule 13D, on September 18, 2020, the Issuer granted to Mr. Chappell an option to purchase 133,760 Shares pursuant to the Issuer’s 2020 Plan.  The Grant vests in twelve equal installments, the first of which occurred on December 31, 2020, with the remaining installments vesting on the first day of each quarter thereafter.
    The transactions effected by the Reporting Persons during the past 60 days that were not previously reported on Schedule D are set forth on Schedule B attached hereto.”


    SIGNATURES
    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.
    Dated:
    June 28, 2021
     
    BLACK HORSE CAPITAL LP
         
     
    By:
    Black Horse Capital Management LLC
    General Partner
         
     
    By:
    /s/ Dale Chappell
       
    Name:
    Dale Chappell
       
    Title:
    Manager


     
    BLACK HORSE CAPITAL MASTER FUND LTD.
         
     
    By:
    /s/ Dale Chappell
       
    Name:
    Dale Chappell
       
    Title:
    Director


     
    CHEVAL HOLDINGS, LTD.
         
     
    By:
    /s/ Dale Chappell
       
    Name:
    Dale Chappell
       
    Title:
    Director


     
    BLACK HORSE CAPITAL MANAGEMENT LLC
         
     
    By:
    /s/ Dale Chappell
       
    Name:
    Dale Chappell
       
    Title:
    Manager


     
    /s/ Dale Chappell
     
    DALE CHAPPELL



    SCHEDULE B
    TRANSACTIONS IN THE SECURITIES OF THE ISSUER EFFECTED BY THE REPORTING PERSONS DURING THE PAST 60 DAYS
    Class of Security
    Amount of Securities
    Purchased/(Sold)
    Price
    Reporting Person
    Date of
    Transaction
    Common Shares
    (12,730)
    $19.4955
    Black Horse Capital LP
    06/16/2021
    Common Shares
    (13,607)
    $19.1731
    Black Horse Capital LP
    06/17/2021
    Common Shares
    (30,186)
    $18.4992
    Black Horse Capital LP
    06/18/2021
    Common Shares
    (9,985)
    $18.2848
    Black Horse Capital LP
    06/23/2021
    Common Shares
    (10,465)
    $18.3749
    Black Horse Capital LP
    06/24/2021
    Common Shares
    (75,000)
    $17.8035
    Black Horse Capital LP
    06/25/2021
    Common Shares
    (34,431)
    $19.3996
    Black Horse Capital Master Fund Ltd.
    06/16/2021
    Common Shares
    (36,284)
    $19.1731
    Black Horse Capital Master Fund Ltd.
    06/17/2021
    Common Shares
    (80,496)
    $18.4992
    Black Horse Capital Master Fund Ltd.
    06/18/2021
    Common Shares
    (26,625)
    $18.2848
    Black Horse Capital Master Fund Ltd.
    06/23/2021
    Common Shares
    (27,906)
    $18.3749
    Black Horse Capital Master Fund Ltd.
    06/24/2021
    Common Shares
    (200,000)
    $17.8035
    Black Horse Capital Master Fund Ltd.
    06/25/2021
    Common Shares
    (111,325)
    $19.4032
    Cheval Holdings, Ltd.
    06/16/2021
    Common Shares
    (131,532)
    $19.1731
    Cheval Holdings, Ltd.
    06/17/2021
    Common Shares
    (291,798)
    $18.4992
    Cheval Holdings, Ltd.
    06/18/2021
    Common Shares
    (96,516)
    $18.2848
    Cheval Holdings, Ltd.
    06/23/2021
    Common Shares
    (101,158)
    $18.3749
    Cheval Holdings, Ltd.
    06/24/2021
    Common Shares
    (725,000)
    $17.8035
    Cheval Holdings, Ltd.
    06/25/2021
    1









    1The sales listed on this Schedule B were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended
    Get the next $HGEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HGEN

    DatePrice TargetRatingAnalyst
    7/13/2022$13.00 → $2.00Buy → Neutral
    ROTH Capital
    7/13/2022$30.00 → $2.00Overweight → Neutral
    Cantor Fitzgerald
    7/13/2022Buy → Neutral
    H.C. Wainwright
    9/10/2021$9.00Buy → Hold
    Jefferies
    9/9/2021Outperform → Neutral
    Credit Suisse
    9/9/2021$36.00 → $28.00Buy
    H.C. Wainwright
    9/9/2021Neutral → Underweight
    JP Morgan
    8/13/2021$25.00 → $24.00Outperform
    Credit Suisse
    More analyst ratings

    $HGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chappell Dale sold $4,250 worth of shares (386,350 units at $0.01) (SEC Form 4)

      4 - HUMANIGEN, INC (0001293310) (Issuer)

      10/20/23 6:50:35 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Hohneker John

      4 - HUMANIGEN, INC (0001293310) (Issuer)

      7/29/22 6:31:06 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Buxton Cheryl

      4 - HUMANIGEN, INC (0001293310) (Issuer)

      7/29/22 6:31:07 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Humanigen Inc. (Amendment)

      SC 13G/A - HUMANIGEN, INC (0001293310) (Subject)

      2/1/23 1:21:00 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Humanigen Inc. (Amendment)

      SC 13D/A - HUMANIGEN, INC (0001293310) (Subject)

      3/17/22 4:28:37 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Humanigen Inc. (Amendment)

      SC 13G/A - HUMANIGEN, INC (0001293310) (Subject)

      2/14/22 4:54:04 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HGEN
    Leadership Updates

    Live Leadership Updates

    See more
    • Omega Therapeutics Announces Appointment of Rainer Boehm to its Board of Directors

      Former Novartis Veteran Brings Deep Expertise in Drug Development and Commercialization CAMBRIDGE, Mass., Sept. 1, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (NASDAQ:OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to using mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced the appointment of Rainer Boehm as an independent director to its Board of Directors. Mr. Boehm will serve on Omega's audit and compensation committees. "Rainer's growth-oriented perspective and global strategic management experience will be invaluable to Omega in this next phase o

      9/1/22 7:00:00 AM ET
      $CLLS
      $HGEN
      $OMGA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Aquestive Therapeutics Strengthens Team to Align with Strategic Focus on Allergy Space

      Appoints Timothy E. Morris, a veteran biotech executive with over 35 years of experience in executive and financial leadership, to Board of DirectorsNames Kenneth Truitt, M.D., with over 25 years of clinical and regulatory experience across biotechnology and large pharmaceutical companies, as Chief Medical Officer Reports inducement grant to Dr. Truitt under Nasdaq Listing Rule 5635(c)(4) WARREN, N.J., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today the appointments of Timothy E. Mo

      8/10/22 4:50:35 PM ET
      $AQST
      $DBVT
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Humanigen Announces Ken Trbovich Appointed as Senior Vice President, Investor Relations

      BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, today announced the appointment of Ken Trbovich to the newly-created role of SVP of Investor Relations, effective immediately, reporting to Timothy E. Morris, COO/CFO of Humanigen. Mr. Trbovich brings to Humanigen 20 years of experience on Wall Street as a Managing Director and Senior Analyst at several leading investment banks including Janney Montgomery Scott, MLV & Co. (now part of B. Riley), C.E. Unterberg, Towbin (now part of C

      6/7/21 8:00:00 AM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HGEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Humanigen - Lenzilumab Being Studied as a Potential First Treatment in Thirty Years with a Novel Mechanism of Action for Chronic Myelomonocytic Leukemia (CMML), an Orphan Form of Leukemia

      CMML is an aggressive, poorly understood cancer; approximately 20% of patients survive three years from diagnosisEleven subjects dosed with lenzilumab and with current standard of care, azacitidineSix evaluable subjects, including those with high risk CMML, demonstrated clinical benefit at three months follow-upLenzilumab appears to be well-toleratedShort Hills, New Jersey and Adelaide, South Australia--(Newsfile Corp. - April 14, 2023) - Humanigen, Inc. (NASDAQ:HGEN), Humanigen Australia Pty Ltd, (Humanigen) and the South Australian Health and Medical Research Institute (SAHMRI) today presented (poster CT085/13); the design and baseline results of the Precision Approach to Chronic Myelomono

      4/14/23 12:05:00 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Humanigen Reports Third Quarter 2022 Financial Results

      Short Hills, New Jersey--(Newsfile Corp. - November 14, 2022) - Humanigen, Inc. (NASDAQ:HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on developing lenzilumab (LENZ®), a first-in class antibody that neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), today reported financial results for the third quarter and nine months ended September 30, 2022.In July 2022, the company announced a strategic realignment of its pipeline, resources and regulatory strategy. The company is accelerating the development of lenzilumab in chronic myelomonocytic leukemia (CMML), a rare blood cancer, for which the PREACH-M study is already underway. The company is also contin

      11/14/22 4:01:00 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Humanigen Announces Participation and Presentation at Jefferies London Healthcare Conference

      Short Hills, New Jersey--(Newsfile Corp. - November 10, 2022) - Humanigen, Inc. (NASDAQ:HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating certain inflammatory and oncological conditions, today announced that Cameron Durrant, MD, MBA, Chairman & CEO, will give a corporate presentation at 11:25am EST (4:25pm local time) at the Jefferies London Healthcare Conference taking place on November 17, 2022. Dr. Durrant will provide an update on the clinical development of lenzilumab, Ifabotuzumab and HGEN005.A livestream will be available and a webcast link to a recording of the event will be posted to the "Events and Presentations" section of Humanige

      11/10/22 8:02:00 AM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HGEN
    SEC Filings

    See more
    • Humanigen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - HUMANIGEN, INC (0001293310) (Filer)

      1/8/24 5:02:09 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by Humanigen Inc.

      25-NSE - HUMANIGEN, INC (0001293310) (Subject)

      10/12/23 8:19:55 AM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Humanigen Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - HUMANIGEN, INC (0001293310) (Filer)

      9/14/23 4:01:46 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HGEN
    Financials

    Live finance-specific insights

    See more
    • Humanigen Announces Conference Call and Webcast to Discuss Lancet Respiratory Medicine Publications and Provide a Corporate Update

      Humanigen, Inc. (NASDAQ:HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,' announced that it will host a conference call and webcast to discuss The Lancet Respiratory Medicine publications and provide a corporate update at 8am EST on December 2, 2021. The peer-reviewed paper in The Lancet Respiratory Medicine is available via the follow link: https://doi.org/10.1016/S2213-2600(21)00494-X The associated comment in The Lancet Respiratory Medicine is available via the following link: https://doi.org/10.1016/S2213-2600(21)00539-7 Details about how to access the conference call and webcast are pr

      12/1/21 6:45:00 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Humanigen downgraded by ROTH Capital with a new price target

      ROTH Capital downgraded Humanigen from Buy to Neutral and set a new price target of $2.00 from $13.00 previously

      7/13/22 9:07:33 AM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Humanigen downgraded by Cantor Fitzgerald with a new price target

      Cantor Fitzgerald downgraded Humanigen from Overweight to Neutral and set a new price target of $2.00 from $30.00 previously

      7/13/22 7:40:18 AM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Humanigen downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Humanigen from Buy to Neutral

      7/13/22 7:39:46 AM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care